An overview of developments in immune-based therapies in the treatment of AML and MDS: Updates from #ASCO23

Patients with myelodysplastic syndrome (MDS) have limited treatment options that offer durable responses, with allogeneic hematopoietic stem cell transplantation increasingly used as a curative option. However, this is associated with relapse and poor survival outcomes. The introduction of immunotherapies such as checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapies have shown promising outcomes in clinical trials.¹

During the American Society of Clinical Oncology (ASCO) Meeting 2023, the progress of several ongoing trials evaluating the efficacy and safety of T-cell-based immunotherapies were presented. We are pleased to present a summary of three poster presentations on: the efficacy and safety of vibecotamab by Nicholas Short²; the antileukemic activity and safety of pivekimab sunirine (PVEK) by Naval Daver³; and a first-in-human trial of tocilizumab by Pierre Peterlin.⁴

Developments in immunotherapies

Most patients with MDS or acute myeloid leukemia (AML) express CD123.² On normal hematopoietic progenitors, CD123 is expressed at incredibly low levels, making it a potentially effective therapeutic target. 

Vibecotamab²

Vibecotamab is a CD3-CD123 bispecific T-cell-engaging antibody (Figure 1) demonstrating clinical activity in patients with relapsed/refractory (R/R) AML. In a phase I study, vibecotamab (dose ≥0.75 µg/kg) demonstrated an overall response rate (ORR) of 26% in patients with ≤25% blasts.

Nicholas Short presented the progress of an open-label, phase II trial of vibecotamab (NCT05285813) in patients with positive measurable residual disease (MRD+) AML, MDS, or chronic myelomonocytic leukemia (CMML) after failure with hypomethylating agents. Patients with either an MRD level of ≥0.1% (by multiparameter flow cytometry), or intermediate/higher-risk MDS, or CMML-1 or CMML-2 are eligible. Enrolled patients are given vibecotamab intravenously (IV) on Days 1 (0.43 µg/kg), 3 (0.75 µg/kg), 5 (1.1 µg/kg), and 8 (1.7 µg/kg) of Cycle 1, followed by a weekly dose of vibecotamab 1.7 µg/kg. The primary endpoint in the MRD+ cohort is the determination of the MRD negativity rate (target 50%), and in the MDS/CMML cohort it is ORR (target 30%) after 4 cycles of vibecotamab.

The trial started in May 2022 and is actively recruiting patients at the MD Anderson Cancer Center. To date, 17 patients have been enrolled, 9 with MRD+ AML and 8 with MDS or CMML. Active recruitment of patients is planned until the end of 2024, with an aim of 20 patients per cohort.

Pivekimab sunirine³

Long-term survival is inadequate in patients with frontline unfit AML, despite improved outcomes with azacitidine (AZA) and venetoclax (VEN) treatment. Pivekimab sunirine (PVEK) is an antibody–drug conjugate (ADC) that contains an indolinobenzodiazepine pseudodimer payload and a cleavable linker and is a high-affinity CD123 antibody (Figure 2A). According to pre-clinical studies, PVEK in combination with AZA and VEN has demonstrated therapeutic synergy. Clinical evidence also supports continued research into PVEK, AZA, and VEN as a combination therapy. Magrolimab is a monoclonal antibody blocking CD47 (Figure 2B). Magrolimab has shown promise as a monotherapy therapeutic for R/R AML in a phase I study.

Daver presented the progress of a phase Ib/II, open-label, multicenter trial (NCT04086264) of PVEK. The trial is comprised of two cohorts:

• Cohort C (PVEK + AZA + VEN regimen) in patients with newly diagnosed CD123+ AML who are unfit for intensive induction therapy.
  • In Cohort C, patients will receive the established recommended phase II dose (RP2D) of PVEK 0.045 mg/kg IV (<30-minute outpatient infusion) plus AZA (75 mg/m² SC or IV) on Days 1–7, and VEN (up to 400 mg PO) daily for 14 days (Cohort 1) or 28 days (Cohort 2).
• Cohort E (PVEK + magrolimab regimen) in patients with R/R CD123+ AML and hemoglobin ≥9 g/dL prior to initial dose of magrolimab.
  • In Cohort E, patients will receive PVEK (IV) on a dose-escalation schedule on Day 1 of the 28-day cycles combined with 30 mg/kg of magrolimab every 2 weeks, after the standard ramp-up schedule.

The primary and key secondary endpoints are listed below:

• Cohort C primary endpoints: antileukemic activity assessed by composite CR rate, ORR, and duration of remission, and MRD levels as assessed by central flow cytometry.
• Cohort E primary endpoints: dose-limiting toxicity (DLT) in the safety phase; and antileukemic activity, as assessed by composite CR rate, ORR, and duration of CR, in the expansion phase.
• Cohort C and E key secondary endpoints: safety and tolerability, pharmacokinetics, and immunogenicity.

Cohort C is currently enrolling patients across 29 sites in France, Germany, Italy, Spain, UK, and USA. Cohort E will open for enrollment mid-2023 at the US sites.

Tocilizumab⁴

Interleukin-6 promotes resistance to chemotherapy and is known to be related to poor prognosis in patients with AML. IL-6 blockade may therefore represent a promising new therapeutic strategy for the management of AML.

Pierre Peterlin presented the early findings from the phase I TOCILAM single-center trial (NCT04547062). This is a first-in-human trial of tocilizumab in combination with standard induction chemotherapy in patients with newly diagnosed AML with a favorable risk, or R/R AML. Three doses of tocilizumab were evaluated: 4, 6, and 8 mg/kg administered on Day 8 of a standard AML induction chemotherapy regimen of idarubicine 8 mg/m² on Days 1–5 plus cytarabine 100 mg/m² on Days 1–7. The primary aim of the trial was to determine the maximum tolerated dose of tocilizumab to inform phase II and III studies.

Key findings

A total of 12 patients were included between December 2020 and 2022 with a median age of 66 years (range, 65–70.5 years) and a median follow-up of 675 days.

• No patients reported DLT from tocilizumab.
• The median levels of IL-6 increased after tocilizumab from 23.2 pg/mL to 202.9 pg/mL and 481.5 pg/mL on Day 8 and 15, respectively.
• The median levels of tocilizumab were also higher at 8 and 15 days after injection: 34.8 µg/ml at the 6 mg/kg dose and 38.5 µg/ml at the 8 mg/kg dose compared with 10.9 µg/ml at 4 mg/kg dose.
  • The RP2D is 8 mg/kg of tocilizumab.
• The overall remission rate for evaluable patients was 90%.
• The most common Grade ≥3 adverse events were bacteremia occurring in 67% and pneumonia in 25% of patients.
• Nine serious adverse events were reported; none were related to tocilizumab.
• Two patients died, one at Day 21 from an infection and the other at Day 15 from a cerebral hemorrhage.

Conclusion

The range of ongoing trials evaluating various immune-based therapeutics for the treatment of MDS and AML are promising. Further findings from these trials will inform the efficacy and safety data of immune-based therapies in the treatment of MDS and AML.